



PRESS RELEASE

FOR IMMEDIATE RELEASE

December 8, 2011

Indel Therapeutics Awarded Key Patent for Novel Antimicrobial Drug Discovery Platform

Vancouver, BC – Indel Therapeutics Inc., a biopharmaceutical company dedicated to developing new drugs to address the global health crisis caused by antibiotic resistance, announced today the issuance of its second patent by the U.S. Patent and Trademark Office strengthening the intellectual property portfolio of its proprietary antimicrobial drug discovery platform technology.

“We are very pleased the U.S. Patent Office approved this patent, recognizing of the inventive nature of Indel’s proprietary antimicrobial drug discovery technology,” said Malcolm Kendall, the Chief Executive Officer of Indel Therapeutics. “The claims in this patent provide broad protection and further strengthen the Company’s intellectual property. We expect to have additional patents issue and to file new patents as we continue to innovate and advance our exciting antimicrobial platform. Indel now has the dominant patent position of any company trying to develop novel antimicrobials that target indel-differentiated regions.”

Indel’s core technology is based on an unexploited and novel antimicrobial targeting paradigm. The Indel platform identifies and targets discrete amino acid insertion or deletion differences (“indels”) between essential homologous proteins that are evolutionarily conserved across the pathogen (bacteria) and humans. Based upon these structural differences, the Company can selectively target the pathogen protein with small molecules without binding to the human counterpart, thereby potentially reducing toxicity and microbial resistance. The patented indel technology opens a rich, new area for developing novel antimicrobials for the treatment of bacterial and parasitic infections and potentially fungal and viral infections.

About Indel Therapeutics

Indel Therapeutics Inc. is a Vancouver-based biopharmaceutical company dedicated to developing new drugs to address the global health crisis caused by antibiotic resistance. The Company has a growing pipeline of novel antibiotic drug discovery programs focused on curing difficult-to-treat and hospital-acquired infections. These programs are based on Indel’s paradigm-changing antimicrobial drug discovery platform, a patented technology that has opened a rich, new area of antimicrobial drug targets for the treatment of infectious diseases, which has the potential to provide an advantage against drug resistance. For more information, please visit www.indelrx.com.

Indel Therapeutics Contact:

Malcolm Kendall, CEO

T: (604) 551-8464

mkendall@indelrx.com